头颈部鳞状细胞癌治疗后PET/增强CT扫描中NI-RADS的评分者间信度
本回顾性研究将80例头颈部鳞状细胞癌患者治疗后监测PET/增强CT及紧邻前次对比图像上传至美国放射学会Cortex云平台,由来自7家机构的8名放射科医生独立评估原发灶和颈部,分配NI-RADS类别。结果显示原发灶和颈部的NI-RADS类别Light κ分别为0.55和0.60,为中等一致性;经验丰富与新手评分者间无显著差异。
要点
- NI-RADS类别在原发灶和颈部的评分者间一致性均为中等(Light κ 0.55和0.60)。
- 描述性术语(lexicon)与对应NI-RADS类别的一致性在原发灶为84.4%,颈部为92.6%。
- 经验丰富与新手评分者之间的观察者间一致性无显著差异。
核心结论
- 8名放射科医生使用NI-RADS评估头颈部鳞状细胞癌治疗后监测影像,原发灶和颈部的NI-RADS类别均达到中等一致性。
研究设计与样本
- 回顾性研究,纳入80例头颈部鳞状细胞癌患者(2014年6月至2016年7月)的治疗后监测PET/增强CT及紧邻前次对比图像,上传至美国放射学会Cortex云平台,由来自7家机构的8名放射科医生独立评估;其中5名经验丰富(>5年经验),3名为新手(<5年经验)。
诊断标准与关键数值
- 原发灶NI-RADS类别Light κ为0.55(95% CI: 0.46, 0.63),颈部为0.60(95% CI: 0.48, 0.69)。
- 原发灶描述性术语Light κ为0.30(95% CI: 0.23, 0.36),颈部为0.31(95% CI: 0.24, 0.37)。
- 描述性术语与对应NI-RADS类别的一致性:原发灶84.4%(540/640),颈部92.6%(593/640)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To evaluate the interrater reliability among radiologists examining posttreatment head and neck squamous cell carcinoma (HNSCC) fluorodeoxyglucose PET/contrast-enhanced CT (CECT) scans using Neck Imaging Reporting and Data System (NI-RADS). Materials and Methods In this retrospective study, images in 80 patients with HNSCC who underwent posttreatment surveillance PET/CECT and immediate prior comparison CECT or PET/CECT (from June 2014 to July 2016) were uploaded to the American College of Radiology's cloud-based website, Cortex. Eight radiologists from seven institutions with variable NI-RADS experience independently evaluated each case and assigned an appropriate prose description and NI-RADS category for the primary site and the neck site. Five of these individuals were experienced readers (> 5 years of experience), and three were novices (< 5 years of experience). In total, 640 lexicon-based and NI-RADS categories were assigned to lesions among the 80 included patients by the eight radiologists. Light generalization of Cohen κ for interrater reliability was performed. Results Of the 80 included patients (mean age, 63 years ± 10 [standard deviation]), there were 58 men (73%); 60 patients had stage IV HNSCC (75%), and the most common tumor location was oropharynx (n = 32; 40%). Light κ for lexicon was 0.30 (95% CI: 0.23, 0.36) at the primary site and 0.31 (95% CI: 0.24, 0.37) at the neck site. Light κ for NI-RADS category was 0.55 (95% CI: 0.46, 0.63) at the primary site and 0.60 (95% CI: 0.48, 0.69) at the neck site. Percent agreement between lexicon and correlative NI-RADS category was 84.4% (540 of 640) at the primary site and 92.6% (593 of 640) at the neck site. There was no significant difference in interobserver agreement among the experienced versus novice raters. Conclusion Moderate agreement was achieved among eight radiologists using NI-RADS at posttreatment HNSCC surveillance imaging. Keywords: CT, PET/CT, Head/Neck, Neck, Neoplasms-Primary, Observer Performance Supplemental material is available for this article. © RSNA, 2021.
引用
- Hsu D, Rath TJ, Branstetter BF, et al. Interrater Reliability of NI-RADS on Posttreatment PET/Contrast-enhanced CT Scans in Head and Neck Squamous Cell Carcinoma. Radiol Imaging Cancer. 2021. PMID: 34018845. doi:10.1148/rycan.2021200131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。